dalteparin has been researched along with Cancer of Larynx in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morrison, S | 1 |
| Aerts, S | 1 |
| Van Rompaey, D | 1 |
| Vanderveken, O | 1 |
1 other study available for dalteparin and Cancer of Larynx
| Article | Year |
|---|---|
Failed Awake Intubation for Critical Airway Obstruction Rescued With the Ventrain Device and an Arndt Exchange Catheter: A Case Report.
Topics: Aged; Airway Obstruction; Bronchoscopy; Catheters; Enoxaparin; Humans; Intubation, Intratracheal; La | 2019 |